On June 28, 2023, S&P Global held the "Creating an Edge, Seizing Sustainability Opportunities—S&P Global Sustainable1 Sustainability Seminar & The Sustainability Yearbook (China Edition) 2023 Launch" event in Shanghai. This is the first sustainability yearbook released by S&P Global for Chinese listed companies, aiming to identify and recognize Chinese enterprises that have demonstrated sustainability advantages in their respective industries. Sino Biopharm stood out from nearly 1,600 companies to become one of the 88 selected enterprises.

S&P Global has published the global edition of "The Sustainability Yearbook" for 16 consecutive years, receiving widespread attention and recognition from stakeholders worldwide. This is the first time S&P Global has released "The Sustainability Yearbook (China Edition)", aiming to identify and recognize Chinese enterprises that have demonstrated sustainability advantages in their respective industries. Nearly 1,600 companies were included in the selection scope for the yearbook, with 88 companies ultimately being selected. According to the selection rules, companies in each industry that are in the top 15% of S&P Global ESG scores, have a score of no less than 30, and are within 30% of the industry's top score are eligible for inclusion in the yearbook.

In November 2022, Sino Biopharm's S&P CSA-ESG score jumped significantly to 45, surpassing 91% of its global peers and placing it at a leading level among its Chinese peers. This inclusion in S&P Global's "The Sustainability Yearbook 2023 (China Edition)" is a further recognition of the improvement in Sino Biopharm's ESG management evaluation.

Sino Biopharm has always upheld the concept of sustainability and is committed to earnestly practicing the Group's corporate mission of "improving the quality and protecting the dignity of human life" through high-quality ESG management. The Group has established and implemented a "three-tier management system" from the "Board of Directors decision-making level" to the "Group senior management level" and the "enterprise executive level". It promotes the comprehensive implementation of the "CARE" ESG governance strategy centered on "Cure, Accessible, Relationship, and Environmental", safeguarding the Group's high-quality sustainable development.

In terms of environmental protection, Sino Biopharm continuously increases its environmental investment, has launched the "Carbon Neutrality Goal and Pathway Planning" project, and promotes the construction of a green manufacturing system and a green industrial chain. The Group's annual investment in environmental governance exceeds RMB 100 million. Its key member companies, Chia Tai Tianqing, has been awarded the national "Green Factory" title, and Chia Tai Qingjiang has been honored with the "2022 Jiangsu Provincial Green Factory" title.

In terms of human development, Sino Biopharm adheres to the talent concept of "creating an excellent employee experience and continuously empowering employee growth", and is committed to continuously building an equal, inclusive, and diverse workplace culture. In 2022, male employees accounted for 53.34% of the Group, and female employees accounted for 46.66%. The Group places great importance on the continuous construction of its talent pipeline. In 2022, 57.80% of the Group's personnel held a bachelor's degree or above, and nearly 70% of middle management personnel were under the age of 40.

In terms of medical accessibility, Sino Biopharm has always focused on the therapeutic fields of oncology, hepatology, surgery/analgesic, and respiratory diseases, continuously expanding its patient coverage and dedicating itself to reducing the suffering of more patients. Its key products have cumulatively treated over 150 million patients. In addition, Sino Biopharm continues to increase its investment in innovative R&D. In 2022, R&D investment reached RMB 4.454 billion, accounting for 15.48% of revenue.

In terms of community investment, Sino Biopharm actively carries out various public welfare and charitable activities. In 2022, the total investment in public welfare amounted to over RMB 66 million, with a total of over 38,000 hours invested in public welfare. The "Clear Sky Program", a public welfare project co-initiated by the Group's key member company Chia Tai Tianqing, has so far covered 29 cities, with a total historical fundraising amount of over RMB 21.81 million.

We believe the concept of "Science for a healthier world". In the future, Sino Biopharm will remain true to its original mission, actively fulfill its corporate citizen responsibilities, seek health and well-being for more patients, and stride forward on the path of pursuing the harmonious development of the company, employees, the environment, and society, with good ESG governance as the cornerstone.